Stratification of patients in NASH clinical trials: A pitfall for trial success
Year: 2020
Type: review
Abstract: Identifying the most effective therapeutic intervention in patients with NAFLD is challenging. Precise stratification in clinical trials is key to ensuring the inclusion of patients who will benefit (and not those who will be harmed) and/or in whom the natural history can be improved. Clinical trials in NAFLD can provide useful information about the individual components that underlie this complex metabolic disorder and the concomitant medications that could interfere with responses to an experimental intervention. However, to date, clinical trial reporting for NAFLD has been suboptimal, limiting our understanding. Frequently dysmetabolic comorbidities and/or daily habits are not reported or adequately accounted for. Herein, we suggest new strategies to integrate the spectra of comorbidities usually present in patients with NAFLD, accounting for the impact of lifestyle, to develop personalised therapeutic approaches. First, the mechanism of action of the drug being explored should be considered. Second, the same proportion of patients with relevant metabolic comorbidities should be maintained from phase II to III clinical trials, if such comorbidities are expected to impact on the treatment response. Third, innovative trial designs, such as the adaptative, umbrella or basket strategies, could be used to increase the efficiency of clinical trials, potentially benefiting patients while reducing costs and enhancing the likelihood of finding a real benefit of the therapy being studied. Finally, alcohol intake and daily exercise should be assessed objectively not only in the screening period but also during follow-up.
Source: JHEP Reports
Authors: Javier Ampuero, Manuel Romero-Gomez
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, patient stratification, clinical trial design, metabolic comorbidities, lifestyle factors, alcohol consumption, physical activity, adaptive trial design, umbrella trials, basket trials, trial reporting quality, personalized treatment
Open Access status: gold
Estimated APC paid: $2,247
Awards: G1613893726, Caracterización fenotípica para determinar la variabilidad individual de la progresión de la fibrosis en la esteatohepatitis no alcohólica, Identificación y evaluación de biomarcadores relacionados con la hipoxia para el diagnóstico no invasivo de la enfermedad hepática grasa no alcohólica y del daño vascular asociado, Transición esteatohepatitis no alcohólica - hepatocarcinoma: biomarcadores y dianas terapéuticas
OpenAlex ID: W3045230961
